Drug intelligence / Profile preview

NAL8776

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

NAL8776 is a transdermal patch formulation of rotigotine, a non-ergoline dopamine agonist, developed by NAL Pharmaceutical Group for the treatment of Parkinson's disease. The patch is designed for once-daily application, providing continuous delivery of rotigotine to maintain stable plasma levels and stimulate dopamine receptors (specifically D1, D2, and D3 subtypes) in the brain. This mechanism mimics the action of endogenous dopamine, helping to manage the motor symptoms associated with Parkinson's disease and other central nervous system disorders. NAL8776 is currently in the preclinical stage of development.

Other names: Rotigotine 1-Day PatchRotigotine1-Day PatchRotigotine-1-Day Patchrotigotine

Targets

DRD3 (Dopamine receptor D3)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on NAL8776.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL8776.

Explore the full profile